NR4A1 and breast carcinoma: A team led by Joseph Sparano from the Albert Einstein College of Medicine in the Bronx, New York, evaluated primary tumors from 600 women who were treated with chemotherapy and endocrine therapy for stage I–III breast cancer that was hormone receptor-positive (HR+).